

FEB-18-2005 FRI 12:01 PM

FAX NO.

P. 01

RECEIVED
CENTRAL FAX CENTER

FEB 18 2005

Smith, Gambrell & Russell, LLP
ATTORNEYS AT LAW

ATLANTA OFFICE
SUITE 3100, PROMENADE II
1830 PEACHTREE STREET, N.E.
ATLANTA, GEORGIA 30309-3552
TELEPHONE
(404) 815-3500
FACSIMILE
(404) 815-3500

Suzannah K. Sundby, Esq.
Direct Dial: 202-263-4332
Direct Fax: 202-263-4352
ssundby@sgrlaw.com

SUITE 800
1800 M STREET, N.W.
WASHINGTON, D.C. 20038
TELEPHONE (202) 263-4300
FACSIMILE (202) 263-4352
WEBSITE WWW.SGRLAW.COM
Established 1893

FLORIDA OFFICE
SUITE 2000, BANK OF AMERICA TOWER
50 NORTH LAURA STREET
JACKSONVILLE, FL 32202
TELEPHONE
(904) 598-0100
FACSIMILE
(904) 598-6300

18 February 2005

Fax

To: USPTO	From: Suzannah K. Sundby
Fax: (703) 872-9306	Phone:
Date: 18 February 2005	Pages: 6 (including cover page)
In re Application of: WANNEMACHER, et al. Serial No.: 09/960,315 Filed: 24 September 2001 For: DEGLYCOSYLATED RICIN TOXIN A-CHAIN VACCINE	Art Unit: 1644 Examiner: F. Pierre VanderVegt Atty. Dckt: 034047.0041 (RIID 99-12A)

The following are being submitted via facsimile to the United States Patent and Trademark Office on 18 February 2005:

1. Response under 37 CFR 1.116

Certificate Mailing or Transmission under 37 C.F.R. 1.8(a)

I hereby certify that this correspondence is being transmitted by facsimile on the date shown below to the United States Patent and Trademark Office at (703) 872-9306

on 18 February 2005, by Suzannah K. Sundby

Signed: 

RECEIVED
CENTRAL FAX CENTER

FEB 18 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

WANNEMACHER, *et al.*

Serial No.: 09/960,315

Filed: 24 September 2001

For: DEGLYCOSYLATED RICIN TOXIN A-CHAIN VACCINE

Art Unit: 1644

Examiner: F. Pierre VanderVegt

Atty. Dckt: 034047.0041

(RIID 99-12A)

RESPONSE UNDER 37 C.F.R. § 1.116

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Mail Stop: AF

Dear Sir:

This is in response to the Office action mailed 7 February 2005, to which the time for response is set to expire 7 May 2005. The pending claims, claims 17, 18, 21-27, 40, and 44-46, were rejected. Reconsideration and entry of the following amendment are respectfully requested.

Amendment to the Claims begin on page 2 of this paper.

Remarks begin on page 4 of this paper.